Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination.
Journal article
Foster WS. et al, (2022), Cell Rep Med
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Journal article
Padron-Regalado E. et al, (2022), Sci Rep, 12
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.
Journal article
van Doremalen N. et al, (2022), Nat Commun, 13
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.
Journal article
Rosadas C. et al, (2022), J Virol Methods, 302
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.
Journal article
Spencer AJ. et al, (2022), EBioMedicine, 77
Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria
Journal article
EWER K., (2022), Frontiers in Immunology
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice.
Journal article
Collins KA. et al, (2021), Sci Rep, 11
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nature medicine
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.
Journal article
LAMBE T. et al, (2020), Nature Medicine
Antigen-specific competitive inhibition of CD4+ T cell recruitment into the primary immune response
Preprint
Spencer AJ. et al, (2020)
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.
Working paper
van Doremalen N. et al, (2020), bioRxiv : the preprint server for biology
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2020), Nat Med
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Journal article
Voysey M. et al, (2020), Lancet
Abstracts from the 3rd Annual Infection and Immunity Meeting: A meeting of the BSI Infection & Immunity Affinity Group Held on Thursday 11 April 2013 at Park Crescent Conference Centre, 229 Great Portland Street, London W1W 5PN
Journal article
(2013), Clinical and Experimental Immunology, 173, 1 - 4